Eloralintide (LY 3841136, CAS 2883634-40-8) is a next-generation amylin receptor agonist designed for advanced metabolic research. Amylin receptor agonists activate the amylin pathway, which influences satiety, gastric emptying, and nutrient handling in non-human test subjects. This differs from GLP-1, GIP, and glucagon receptor agonists, which act on separate metabolic signaling systems. GLP-1 agonists primarily modulate appetite and glucose dynamics, GIP agonists influence nutrient-driven insulin responses, and glucagon receptor agonists affect energy expenditure. Amylin agonists complement these pathways by providing a direct satiety-focused mechanism.
Eloralintide features an extended half-life that supports once-weekly administration in non-human test subjects, maintaining stable plasma levels throughout research protocols. In controlled studies, test subjects exposed to Eloralintide show dose-dependent reductions in food intake and measurable alterations in metabolic markers, making it a valuable tool for examining long-duration satiety regulation.
In head-to-head research comparisons with other amylin receptor agonists, Eloralintide demonstrates superior performance. Pramlintide, a short-acting analog, produces modest effects but requires frequent administration in test subjects. Cagrilintide, a long-acting amylin agonist, produces stronger appetite-related outcomes, yet Eloralintide often surpasses it in consistency and potency. Eloralintide has shown weight-related reductions in non-human models approaching 9 to 20 percent, while Cagrilintide typically produces approximately 10 to 12 percent reductions under similar study conditions.
Eloralintide also complements multi-pathway compounds such as Semaglutide, Tirzepatide, and Retatrutide, which act through GLP-1, GIP, and glucagon pathways. Its amylin-specific actions provide a distinct and synergistic research avenue.
Overall, Eloralintide serves as a precise and efficient research peptide for studying amylin receptor function and metabolic modulation exclusively in non-human test subjects.
Summary of Characteristics
| Property | Details |
|---|---|
| Chemical Sequence of Amino Acids | {γGlu}-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gly-{Orn}-Leu-Ala-Glu-{(α-Me-Phe)}-Leu-Val-Arg-Ser-Ser-Asn-{(N-Me-Asn)}-Phe-Gly-Pro-{Lys(γGlu-γGlu-C20 diacid)}-Leu-Pro-Pro-Thr-Glu-Val-Gly-Ser-Asn-Thr-Tyr-NH2 (Methylene bridge: Cys2-Cys7) |
| CAS Number | 2883634-40-8 |
| Molecular Formula | C201H319N49O65S2 |
| Molecular Weight | 4526.10 |
| Other Known Titles | LY 3841136, Eloralintide |
